We strive for supporting your translational research.
From biomarker discovery, high-throughput metabolic screening to the optimization and development of novel laboratory assays. Our Research Division has profound experience to support your research activities with cutting-edge technologies.
Stay in touch with us to read about our research activities, accomplishments and publications and register for our monthly ARCHIMEDlife newsletter.
We are your industrial partner with a highly experienced team and laboratory instruments for your academic research activities. We have started ARCHIMEDlife Research Institute as an initiative for „bench to bedside“ medical research. We combine several strategies in translational research to advance progress from laboratory discovery to application, and final access for patients. A research process involves clinicians and researchers working together to solve health challenges faster.
Apply for a research grant? Increase your chance by collaborating with us – a service partner with a highly experienced research team and cutting-edge technologies. We have conduced successfully dozens of studies, and supported research teams worldwide with analytical services.
Several translational research projects are underway at ARCHIMEDlife Research Institute, including:
Contact, discuss and share your ideas with us: research@archimedlife.com
Metabolic Research
We have several Mass Spectrometry instruments (e.g. SCIEX 6500 QQQ, Thermo Fischer Scientific Orbitrap TM) for quantification of small molecules and discovery of novel biomarkers.
Genetic Research
We are highly experienced in the development of novel genetic tests using state-of-the-art molecular biology methods including Next-Generation Sequencing. We support your biochemical research by genetic testing for e.g. genotype-phenotype metabolic diseases studies or tumor biology.
We offer complete laboratory services (sample management, measurement and bioinformatics) for Small Molecule and Protein Profiling.
Contact us research@archimedlife.com to learn more about our dozens of assays for amino acids and metabolic breakdown molecules, acylcarnitines and fatty acids, steroids, peptides and many more.
BIOCRATES Life Science Kits: We are a laboratory service partner for metabolic profiling using BIOCRATES AbsoluteIDQ® p180 Kit. This Kit quantifies up to 188 metabolites from 5 substance classes (hexose, amino acids, biogenic amines, lipids and acylcarnitines), giving the most comprehensive overview of metabolism in a single assay. It has proven to provide highly accurate and highly reproducible information on the metabolic phenotype used in diverse applications such as Cardiometabolic Diseases, Neurology, and Oncology.
Identifying relevant biomarkers is to find a needle in a haystack. Nonetheless, biomarkers become more and more important in diagnostic applications, to help to detect or to predict diseases. Biomarkers are mandatory to move towards a more personalized medicine. Highly disease-specific biomarkers hold great promise to monitor progression of disease of patients without or under therapy.
We, at ARCHIMEDlife Research Institute, put significant effort into the discovery and testing of novel biomarkers.
Contact us biomarkers@archimedlife.com to discuss your biomarker project.
Diagnostics ・R & D・Technologies
on 14 Mrz, 2018
Our awarded work (Poster Finalist at MSACL Europe, also see the PDF Poster Hemoglobinopathies_MSACL) on hemoglobinopathies and thalassemias is now starting into a prospective study in cooperation with the University Medical Center Hamburg-Eppendorf,...
Read More
on 12 Nov, 2017
You can easily subscribe to our bi-monthly ARCHIMEDlife Newsletter and read about laboratory diagnostics, research studies, scientific publications and rare diseases – first hand and for free! If you do not want...
Read Moreon 13 Sep, 2017
We are proud to be a regular part of MSACL – this year in Salzburg from 10.- 14. September 2017. Together with many other leading academic and industrial experts we explore and...
Read Moreon 25 Jul, 2017
An updated Consensus Guideline by worldwide experts is now available: See the publication of CLSI document NBS04-Ed2, Newborn Screening by Tandem Mass Spectrometry. The document is now available by the Clinical & Laboratory...
Read More
on 05 Jul, 2017
Background: Fabry disease (FD) is a rare X-linked lysosomal storage disease caused by mutations in the α-galactosidase A (GLA) gene causing deficiency of α-galactosidase A which results in progressive glycosphingolipid accumulation, especially...
Read More
on 16 Jun, 2017
Background: Fabry disease (FD), an X-linked lysosomal storage disorder, results from the deficient activity of α-galactosidase A (α-Gal A) and the accumulation of its substrates, globotriaosylceramide (Gb3) and its deacylated derivative, globotriaosyl-sphingosine...
Read Moreon 03 Jan, 2017
Background: Fabry disease is an X-linked lysosomal storage disorder due to α-galactosidase A (α-Gal A) deficiency. Clinical onset of Fabry disease is preceded by significant storage of globotriaosylceramide (Gb3) and related glycosphingolipids,...
Read More
on 19 Okt, 2016
Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder due to mutations in the a-galactosidase A gene (GLA) that result in absent or markedly reduce a-galactosidase A (a-GalA) enzymatic activity. As...
Read More
on 21 Jun, 2016
Background: In classical homocystinuria (HCU, MIM# 236200) due to the deficiency of cystathionine β-synthase (EC 4.2.1.22) there is a clear evidence for the success of early treatment. The aim of this study...
Read More
on 24 Mrz, 2016
High consanguinity rates, poor access to accurate diagnostic tests, and costly therapies are the main causes of increased burden of lysosomal storage disorders (LSDs) in developing countries. Therefore, there is a major...
Read More
